{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T07:17:30Z","timestamp":1783840650322,"version":"3.55.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose is to describe management of adverse events of special interest across tyrosine kinase inhibitors approved for metastatic renal cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review in metastatic renal cell carcinoma patients initiating tyrosine kinase inhibitor monotherapy between 15 November 2010 and 15 November 2013, and experiencing\u2009\u2265\u20091 adverse events of special interest (diarrhea, fatigue, hand-foot syndrome, hypertension, or stomatitis\/mucositis) within 3 months of initiation. Demographics, medical history, treatment regimens, and adverse events of special interest management data for 3.5 months postonset were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 220 charts from 27 centers, tyrosine kinase inhibitors prescribed included sunitinib (55%), pazopanib (27%), axitinib (9%), and sorafenib (8%). During the study period, patients experienced 376 adverse events of special interest (13% serious). Fatigue was most common (62% of patients), followed by hypertension (37%), diarrhea (30%), stomatitis\/mucositis (29%), and hand-foot syndrome (12%). Over half (56%) the adverse events of special interest were resolved or resolving. Treatment discontinuation due to adverse events of special interest occurred in 15% of patients. Prophylaxis was rarely provided (8%), whereas 59% of patients received adverse events of special interest treatment (pharmacologic (55%) and\/or nonpharmacologic (7%)), 27% received tyrosine kinase inhibitor dose management, 23% received both adverse events of special interest treatment and dose management, and 31% received neither. Hypertension was the most treated (72% of all events), and fatigue was the least treated (9%); only 4% of patients received pharmacologic treatment for fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most adverse events of special interest were nonserious and more than half of the patients received pharmacologic and\/or nonpharmacologic treatment. Fatigue was the most common yet least frequently treated adverse event of special interest, and few patients received prophylaxis or nonpharmacologic treatment. More emphasis on treatment and prophylaxis options for bothersome adverse events is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155217719583","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T02:56:12Z","timestamp":1500692172000},"page":"574-583","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma"],"prefix":"10.1177","volume":"24","author":[{"given":"Sandy","family":"Srinivas","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Stanford University Medical Center, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"Stein","sequence":"additional","affiliation":[{"name":"Safety, Epidemiology, Registries, and Risk Management (SERRM), United BioSource Corporation, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Y","family":"Teltsch","sequence":"additional","affiliation":[{"name":"Real-World Evidence, Evidera, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunning","family":"Tao","sequence":"additional","affiliation":[{"name":"Safety, Epidemiology, Registries, and Risk Management (SERRM), United BioSource Corporation, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cisar","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Pfizer Inc, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Outcomes and Evidence, Pfizer Inc, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"bibr1-1078155217719583","first-page":"51","volume":"2","author":"Schwandt A","year":"2009","journal-title":"Onco Targets Ther"},{"key":"bibr2-1078155217719583","volume-title":"Kidney cancer \u2013 renal cell cancer treatment \u2013 patient version (PDQ\u00ae)","author":"National Cancer Institute","year":"2015"},{"key":"bibr3-1078155217719583","volume-title":"Kidney cancer (adult)\u2009-\u2009renal cell carcinoma","author":"American Cancer Society","year":"2014"},{"key":"bibr4-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"bibr5-1078155217719583","volume-title":"Update on tyrosine kinase inhibitors (TKI) in metastatic renal cell carcinoma","author":"Azvolinsky A","year":"2011"},{"key":"bibr6-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.574"},{"key":"bibr7-1078155217719583","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.11273"},{"key":"bibr8-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds227"},{"key":"bibr9-1078155217719583","volume-title":"NCCN clinical practice guidelines in oncology \u2013 kidney cancer (NCCN Guidelines\u00ae v1.2015)","author":"National Comprehensive Cancer Network","year":"2015"},{"key":"bibr10-1078155217719583","volume-title":"Sutent\u00ae (sunitinib malate) prescribing information","author":"Pfizer Inc","year":"2006"},{"key":"bibr11-1078155217719583","volume-title":"Votrient\u00ae (pazopanib) tablets prescribing information","author":"Novartis Pharmaceuticals Company","year":"2009"},{"key":"bibr12-1078155217719583","volume-title":"Nexavar\u00ae (sorafenib) prescribing information","author":"Bayer Healthcare Pharmaceuticals Inc","year":"2010"},{"key":"bibr13-1078155217719583","volume-title":"Inlyta\u00ae (axitinib) prescribing information","author":"Pfizer Inc","year":"2012"},{"key":"bibr14-1078155217719583","unstructured":"Exelixis Inc.\n                      Cabozantinib (Cabometyx\u00ae) prescribing information\n                      . San Francisco, CA: Exelixis Inc, 2016."},{"key":"bibr15-1078155217719583","unstructured":"Eisai Inc. Lenvatinib (Lenvima\u00ae) prescribing information. Woodcliff, NJ: Esai Inc, 2016."},{"key":"bibr16-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1170-y"},{"key":"bibr17-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.73"},{"key":"bibr18-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr511"},{"key":"bibr19-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0263"},{"key":"bibr20-1078155217719583","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2181"},{"key":"bibr21-1078155217719583","volume-title":"Clinical practice guidelines in oncology: cancer-related fatigue, version I","author":"National Comprehensive Cancer Network","year":"2016"},{"key":"bibr22-1078155217719583","unstructured":"Groupe d\u2019\u00c9tude en Oncologie du Qu\u00e9bec (GEOQ).\n                      OnTarget resource guide: common side effects of targeted therapy\n                      . Montreal, QC, Canada: Groupe d\u2019\u00c9tude en Oncologie du Qu\u00e9bec. 2012."},{"key":"bibr23-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.10.018"},{"key":"bibr24-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1515-7"},{"key":"bibr25-1078155217719583","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0461-x"},{"key":"bibr26-1078155217719583","first-page":"26","volume":"35","author":"Lindsey H","year":"2013","journal-title":"Oncol Times"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217719583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217719583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217719583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:29Z","timestamp":1777688249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217719583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1177\/1078155217719583"],"URL":"https:\/\/doi.org\/10.1177\/1078155217719583","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]}}}